Roche Holding AG banner

Roche Holding AG
SWB:RHO6

Watchlist Manager
Roche Holding AG Logo
Roche Holding AG
SWB:RHO6
Watchlist
Price: 42.5 EUR 0.71%
Market Cap: €396.3B

P/E

20.1
Current
1%
More Expensive
vs 3-y average of 19.9

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
20.1
=
Market Cap
€279.8B
/
Net Income
CHf12.9B

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
20.1
=
Market Cap
€279.8B
/
Net Income
CHf12.9B

Valuation Scenarios

Roche Holding AG is trading above its 3-year average

If P/E returns to its 3-Year Average (19.9), the stock would be worth €42.09 (1% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-3%
Maximum Upside
+47%
Average Upside
12%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple 20.1 €42.5
0%
3-Year Average 19.9 €42.09
-1%
5-Year Average 19.4 €41.07
-3%
Industry Average 29.5 €62.37
+47%
Country Average 21.4 €45.36
+7%

Forward P/E
Today’s price vs future net income

Today's Market Cap Net Income Forward P/E
€279.8B
/
Jan 2026
CHf12.9B
=
20.1
Current
€279.8B
/
Dec 2026
CHf16.7B
=
16.8
Forward
€279.8B
/
Dec 2027
CHf17.8B
=
15.7
Forward
€279.8B
/
Dec 2028
CHf19.2B
=
14.5
Forward

Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.

Peer Comparison

All Countries
Close
Earnings Growth PEG
CH
Roche Holding AG
SWB:RHO6
Average P/E: 21.3
20.1
14%
1.4
US
Eli Lilly and Co
NYSE:LLY
44.6
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
26.2
8%
3.3
UK
AstraZeneca PLC
LSE:AZN
27.7
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
15.3
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1
FR
Sanofi SA
PAR:SAN
10.2
16%
0.6

Market Distribution

Lower than 97% of companies in Switzerland
Percentile
3rd
Based on 909 companies
3rd percentile
2.6
Low
0.2 — 16.5
Typical Range
16.5 — 29.9
High
29.9 —
Distribution Statistics
Switzerland
Min 0.2
30th Percentile 16.5
Median 21.4
70th Percentile 29.9
Max 546

Roche Holding AG
Glance View

Roche Holding AG, a titan in the world of healthcare, operates from its headquarters in Basel, Switzerland. Established in 1896, Roche has grown into one of the world's leading pharmaceutical and diagnostics companies, driven by a steadfast commitment to advancing medicine and improving lives. Its unique business model is built on two primary pillars: Pharmaceuticals and Diagnostics. The pharmaceutical division focuses on discovering and developing medicines for cancer, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. A significant portion of its revenue is generated from innovative oncology drugs, which positions Roche as a global leader in cancer treatment. The company's investment in research and development is notably high, emphasizing its dedication to scientific discovery. On the diagnostics front, Roche continually advances its technologies to enhance disease detection and monitoring. This division creates and sells a wide array of diagnostic products and services, ranging from clinical chemistry and immunoassays to molecular biology and tissue diagnostics. By serving hospitals, research labs, and healthcare professionals, Roche Diagnostics aims to make a crucial impact on patient care and health system efficiency. This dual focus on pharmaceuticals and diagnostics allows Roche to capitalize on synergies between drug development and patient diagnostics, often integrating their advancements to provide more tailored and efficient healthcare solutions. The company's financial strength and strategic innovation are underpinned by its ability to adapt to changing market dynamics, ensuring its place as a stalwart in the global healthcare industry.

RHO6 Intrinsic Value
59.71 EUR
Undervaluation 29%
Intrinsic Value
Price €42.5
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett